Cargando…

Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

INTRODUCTION: There is an increasing interest for real-life data on drug use in many countries. Reimbursement authorities more and more request observational studies to assess the conditions of use of the products but also to improve knowledge about efficacy and safety in the real world and on a lon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Dominique, Detournay, Bruno, Eschwege, Evelyne, Bouée, Stephane, Bringer, Jacques, Attali, Claude, Dejager, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065290/ https://www.ncbi.nlm.nih.gov/pubmed/24729158 http://dx.doi.org/10.1007/s13300-014-0064-0

Ejemplares similares

Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study
por: Halimi, Serge, et al.
Publicado: (2013)

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
por: Schweizer, Anja, et al.
Publicado: (2013)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA
por: Fofonka, Aline, et al.
Publicado: (2014)

Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management
por: Dejager, Sylvie, et al.
Publicado: (2011)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
por: Detournay, Bruno, et al.
Publicado: (2015)

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017)

Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
por: Emery, Corinne, et al.
Publicado: (2020)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
por: Pan, CY, et al.
Publicado: (2013)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
por: Roussel, Ronan, et al.
Publicado: (2016)

Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
por: Roussel, Ronan, et al.
Publicado: (2020)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is this of concern?
por: Monnier, Louis, et al.
Publicado: (2013)

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz, Kamran MA
Publicado: (2015)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
por: Göke, Rüdiger, et al.
Publicado: (2014)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_94lgjma89vu5h3imnkbjcgmejf